Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Nov 2023

Stephenson Kimberly G, Lingle Abby J, Baumberger Kelly A, Dellon Elisabeth P, Esther Charles R, Meier Ellen M, Oermann Christopher M, Shenoy Vivek K, Smith Natalie R, Wimmer Nicole S, Duehlmeyer Stephanie R, Kam Charissa W, McKinzie Cameron J, Poisson Margaret O, Elson E Claire

Abstract excerpt

BACKGROUND: Improvement in exocrine pancreatic function in persons with CF (pwCF) on cystic fibrosis transmembrane conductance regulator (CFTR) modulators has been documented in clinical trials using fecal pancreatic elastase-1 (FE-1). Our group endeavored to evaluate real-world data on FE-1 in children on CFTR modulator therapy at three pediatric cystic fibrosis (CF) centers. METHODS: Pediatric pwCF were offered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Cystic Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Mutation

Share to Pancreas

Share to Pancreatic Elastase

Source

Identifiers

PMID: 37758535
DOI: 10.1016/j.jcf.2023.09.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis.PMID 37758535Read ↗

Use of monoclonal faecal elastase-1 concentration for pancreatic status assessment in cystic fibrosis patients.Semantic proximity Read ↗

Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis.Semantic proximity Read ↗

Evaluation of fecal pancreatic elastase-1 as a measure of pancreatic exocrine function in children with cystic fibrosis.Semantic proximity Read ↗

Evolution of pancreatic function during the first year in infants with cystic fibrosis.Semantic proximity Read ↗

Early decline of pancreatic function in cystic fibrosis patients with class 1 or 2 CFTR mutations.Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review.Semantic proximity Read ↗

Improving Pancreatic Function With Elexacaftor/Tezacaftor/Ivacaftor.Semantic proximity Read ↗

Longitudinal follow-up of exocrine pancreatic function in pancreatic sufficient cystic fibrosis patients using the fecal elastase-1 test.Semantic proximity Read ↗

CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis.Semantic proximity Read ↗

Fecal elastase: pancreatic status verification and influence on nutritional status in children with cystic fibrosis.Semantic proximity Read ↗

Benefits of reviewing pancreatic function in children with cystic fibrosisSemantic proximity Read ↗

Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.